Non-vitamin K oral anticoagulants in valvular heart disease before surgery: a tale of bridging vs. no bridging
Patients with atrial brillation on a non-vitamin K antagonist oral anticoagulant scheduled for low-or high-bleeding-risk surgery (including bioprosthetic valve implantation or valve repair) Very high thrombotic risk (e.g., CHA 2 DS 2 VASc 7 or more) Consider bridging with a LMWH No bridging Dabigatran 24h 36h 48h 48h 72h 96h Apixaban -Edoxaban -Rivaroxaban CrCl 80mL/min Not
Authors
- Vittorio Pengo (ORCID: https://orcid.org/0000-0003-2064-6071)
- Hugo Ten Cate (ORCID: https://orcid.org/0000-0001-7796-4463)
- Raffaele De Caterina (ORCID: https://orcid.org/0000-0003-1637-574X)
Institutions
- University of Pisa (IT)
- University of Padua (IT)
- Maastricht University Medical Centre (NL)
Publication Details
- Journal
- European Heart Journal
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1093/eurheartj/ehae615
- Citations
- 3
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.21